Tirzepatide vs Semaglutide: How to Track the Differences

Tirzepatide (Mounjaro / Zepbound) and semaglutide (Ozempic / Wegovy) are the two most-discussed metabolic peptides of the last few years. Both are weekly subcutaneous injections, both are titrated up over months, and both come with side effects that the user has to manage actively. The tracking problem is the same shape — but the details differ.

Mechanism in one paragraph

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 / GIP receptor agonist — meaning it hits a second incretin pathway in addition to GLP-1. In practice, tirzepatide trials show larger average weight loss at comparable doses, with a side-effect profile that overlaps but is not identical.

Titration shape

• Semaglutide: typical stepped titration over 16 weeks to target (e.g., 0.25 → 0.5 → 1 → 1.7 → 2.4 mg weekly).
• Tirzepatide: typical stepped titration to 5 → 7.5 → 10 → 12.5 → 15 mg weekly.

The structure is identical: change dose, hold for ~4 weeks, evaluate, step up if tolerable.

What to track for both

Daily:

• Appetite (1–10)
• Nausea (0–10)
• GI symptoms (bloating, constipation, reflux)
• Hydration intake (ml or cups)
• Energy

Weekly:

• Weight (same scale, same time)
• Waist circumference
• Photos (front/side/back)
• Workout performance

At every titration step:

• New dose
• Date of first administration
• Side effects in the first 7 days at the new step
• Any dose hold or step-back

Where the two differ in your log

Tirzepatide users more often report:

• Sulphurous burps (a quirk of GIP receptor activation)
• Larger weight loss per week at equivalent steps
• More appetite suppression at the same subjective hunger score

Semaglutide users more often report:

• Slower, more predictable taper of side effects week-by-week
• More consistent injection-site reactions
• Slightly less pronounced early-titration nausea

These are tendencies, not rules — individual variation dominates. Your log is the only authoritative source for your response.

A clean comparison protocol

If you want personal data comparing the two:

1. Run semaglutide titration to a stable maintenance dose for at least 8 weeks. Track daily.
2. Wash-out: at least 8 weeks off, continue tracking.
3. Run tirzepatide titration to a stable maintenance dose for at least 8 weeks. Track daily.
4. Compare the two windows: appetite, weight delta, side-effect intensity, energy, performance.

This isn't fast, but it is the only way to honestly compare the two in your body.

Things that confound the comparison

• Caloric intake changes between protocols. If you eat 300 fewer calories on tirzepatide than semaglutide, the protocols aren't being compared — your food intake is.
• Training changes. Hold training constant during comparison windows.
• Sleep, alcohol, stress. All affect weight more than the difference between the two drugs.

Cost and access

Both are prescription medications in major markets. Off-label or compounded use is common but legally and clinically distinct from prescribed use. Track which source you're using; the formulation matters and varies.

Bottom line

Track the same metrics for both. Hold confounders constant. Give each protocol enough time at maintenance dose to evaluate honestly. After two clean cycles you'll have real personal data — far better than internet anecdotes.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.